Treatment for glioblastoma (GBM)
Intended for US audiences only.
Optune® Novocure™

Explore the system

The Second Generation Optune System
Smaller. Lighter. Designed for everyday life.

Novocure™ is pleased to introduce the second generation Optune System. It is smaller and lighter, weighing just 2.7 lbs.

Optune® Components

Optune components

The complete system includes a portable electric field generator, transducer arrays, rechargeable batteries, and more.
Optune® Electric Field Generator

Electric field generator

The portable field generator can be carried with you to generate Tumor Treating Fields (TTFields) as you go about your day.
Optune® Transducer Array

Transducer array

Sterile, single-use transducer arrays are connected to the electric field generator to deliver therapy. Transducer arrays are generally changed at least 2 times per week (every 4 days at most).
Optune® Connection Cable

Connection cable and box

Black and white coded sockets on the cable box help ensure that transducer arrays are properly connected.

Easy access sleeve bag

Openings conveniently located at the top and bottom make it easy to reach device controls

Convertible, 5-in-1 bag

This bag can be worn 5 different ways and has additional battery storage, making it ideal for on-the-go use.

The second generation Optune System offers features that enhance carrying comfort and usability:

  • Easy-grip texture allows for better handling

  • Battery indicator displays power and alerts you when it’s time to change the battery

  • Light-detecting sensor auto-dims the device and the charger in the dark

Other components include:

  • Portable batteries: 4 batteries are provided with each kit; each battery lasts for 2 to 3 hours

  • Charger for portable batteries: Batteries will need to be recharged for 2 to 4 hours. The batteries can be charged and used many times for about 6 to 9 months

  • Plug-in power supply and power cords: New “No-Stop Swap” enables you to swap batteries or power source without disrupting delivery of TTFields

1. Optune Patient Information and Operation Manual. Novocure 2016.

Find a certified prescriber

Locate a nearby treatment center where doctors are certified to prescribe Optune.

Find a certified center

Complete support

Learn how nCompass supports Optune users every step of the way.

Discover nCompass
Find a Treatment Center

OPT-041.3-10


CONTACT AN OPTUNE EXPERT

What is Optune® approved to treat?

Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:

Recurrent GBM

If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:

Who should not use Optune?

Optune is not for everyone. Talk to your doctor if you have:

Do not use Optune if you are pregnant or are planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.

What should I know before using Optune?

Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure™, the maker of Optune.

What are the possible side effects of Optune?

Most common side effects of Optune when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.

The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.

Talk to your doctor if you have any of these side effects or questions.


Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).